Cargando…
Contraceptive risk : the FDA, Depo-Provera, and the politics of experimental medicine.
The story of Depo-Provera joins the national struggle over the drug's FDA approval to the state legal issues raised by its contraceptive and criminal justice uses.Depo-Provera is known as an injectable hormonal birth control method, but few are familiar with its dark and complicated history. De...
| Clasificación: | Libro Electrónico |
|---|---|
| Autor principal: | |
| Formato: | Electrónico eBook |
| Idioma: | Inglés |
| Publicado: |
New York :
NYU Press,
2017.
|
| Colección: | Biopolitics--the bio-environment.
|
| Temas: | |
| Acceso en línea: | Texto completo |
MARC
| LEADER | 00000cam a2200000Mi 4500 | ||
|---|---|---|---|
| 001 | JSTOR_ocn982451134 | ||
| 003 | OCoLC | ||
| 005 | 20231005004200.0 | ||
| 006 | m o d | ||
| 007 | cr |n|---||||| | ||
| 008 | 170422s2017 nyu o 000 0 eng d | ||
| 040 | |a EBLCP |b eng |e pn |c EBLCP |d OCLCO |d ESU |d OCLCQ |d JSTOR |d OCLCF |d OCLCQ |d RDF |d S1C |d OCLCO |d OCLCQ |d OCLCO | ||
| 020 | |a 9781479825929 |q (electronic bk.) | ||
| 020 | |a 1479825921 |q (electronic bk.) | ||
| 035 | |a (OCoLC)982451134 | ||
| 037 | |a 22573/ctt1ggjx55 |b JSTOR | ||
| 043 | |a n-us--- | ||
| 050 | 4 | |a RG136 | |
| 050 | 4 | |a RG137.6.M43 |b G74 2017 | |
| 072 | 7 | |a POL |x 028000 |2 bisacsh | |
| 072 | 7 | |a LAW |x 001000 |2 bisacsh | |
| 082 | 0 | 4 | |a 618.1/8 |2 23 |
| 049 | |a UAMI | ||
| 100 | 1 | |a Green, William, |d 1950- |e author. | |
| 245 | 1 | 0 | |a Contraceptive risk : |b the FDA, Depo-Provera, and the politics of experimental medicine. |
| 260 | |a New York : |b NYU Press, |c 2017. | ||
| 300 | |a 1 online resource (241 pages) | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 490 | 1 | |a Biopolitics | |
| 588 | 0 | |a Print version record. | |
| 505 | 0 | 0 | |t Introduction : the odyssey of Depo-Provera -- |t The Grady Hospital study : the corruption of contraceptive research -- |t The twenty-five-year FDA approval controversy : cancer and the politics of acceptable risk -- |t Contraceptive chaos : unapproved use and Upjohn v. MacMurdo -- |t Marketing approval and litigation : osteoporosis and the realities of medical risk -- |t Chemical castration : the John Hopkins Clinic and People v. Gauntlett -- |t Conclusion : contraceptive drug risk failure, human dignity, and a duty to act. |
| 520 | |a The story of Depo-Provera joins the national struggle over the drug's FDA approval to the state legal issues raised by its contraceptive and criminal justice uses.Depo-Provera is known as an injectable hormonal birth control method, but few are familiar with its dark and complicated history. Depo-Provera was tested on women since the mid-1960s without their informed consent until it was FDA-approved in 1992, but never FDA-approved as chemical castration for male sex offenders.Contraceptive Risk is William Green's landmark study of Depo-Provera. Based on a fascinating combination of archival materials and interviews, the book is framed as three interconnected stories told by Judith Weisz, who chaired the FDA's Public Board of Inquiry on Depo-Provera, a scientific court; by Anne MacMurdo who brought a products liability suit against Upjohn, the drug's manufacturer, for the deleterious side effects she suffered from the drug's use; and by Roger Gauntlett, an Upjohn heir who, when he was convicted of sexual assault, refused to take a dose of his family's own medicine as a probation condition. Together these three stories of Depo-Provera's convoluted fifty year odyssey call for a paradigm shift in pharmaceutical drug development.Contraceptive Risk is a thoroughly researched and engrossing approach to the scientific, political and institutional forces involved in health law and policy, as well as the multifaceted politics of measuring risk. | ||
| 590 | |a JSTOR |b Books at JSTOR All Purchased | ||
| 590 | |a JSTOR |b Books at JSTOR Demand Driven Acquisitions (DDA) | ||
| 650 | 0 | |a Medroxyprogesterone |z United States. | |
| 650 | 0 | |a Contraceptive drugs, Injectable |z United States |x Safety measures. | |
| 650 | 0 | |a Women |x Health risk assessment |z United States. | |
| 650 | 6 | |a Médroxyprogestérone |z États-Unis. | |
| 650 | 6 | |a Médicaments contraceptifs injectables |z États-Unis |x Sécurité |x Mesures. | |
| 650 | 6 | |a Femmes |x Risques pour la santé |x Évaluation |z États-Unis. | |
| 650 | 7 | |a POLITICAL SCIENCE |x Public Policy |x General. |2 bisacsh | |
| 650 | 7 | |a Medroxyprogesterone |2 fast | |
| 650 | 7 | |a Women |x Health risk assessment |2 fast | |
| 651 | 7 | |a United States |2 fast | |
| 776 | 0 | 8 | |i Print version: |a Green, William. |t Contraceptive Risk : The FDA, Depo-Provera, and the Politics of Experimental Medicine. |d New York : NYU Press, ©2017 |z 9781479876990 |
| 830 | 0 | |a Biopolitics--the bio-environment. | |
| 856 | 4 | 0 | |u https://jstor.uam.elogim.com/stable/10.2307/j.ctt1ggjjs5 |z Texto completo |
| 938 | |a EBL - Ebook Library |b EBLB |n EBL4714295 | ||
| 994 | |a 92 |b IZTAP | ||